Search the repository

A+ | A- | | SLO | ENG

Abstract: The bee-mimicking hoverfly species Criorhina pachymera shows pronounced geographical variation in abdominal colour pattern. Based on 218 records from 22 European countries, we describe six abdomen forms divided over two main groups. Group A in western, northern and central parts of Europe contains abdomen forms A1–A3 with slender pollinose bands on the third and fourth tergite. Group B in south-eastern Europe contains forms B1–B3 with broad pollinose bands. These groups are separated by the Alps and the Carpathians, such as the separation of the original distributions of the two main postglacial recolonization lineages of honey bees in Europe. As these honey bee groups differ by the width of the pollinose bands on the third to fifth tergite, Batesian mimicry can explain the group distribution of C. pachymera with slender or broad pollinose bands. The different forms of C. pachymera in both groups are categorised by the extent of orange colouration on the second and third tergite. The darkest form A1, has a widespread distribution in Europe. Intermediate bright forms A2 and A3 occur predominantly in a belt along the southern margin of the group A distribution and in Sweden. Dark form B1 and intermediate bright form B2 occur on the Balkan peninsula and in neighbouring regions. The brightest form B3, is found in Italy, Switzerland (Ticino) and Greece. There is an average increase in the extent of orange colouration on the second and third tergite with decreasing geographical latitude, making temperature a likely additional cause for the described abdominal colour variation.
Keywords: hoverflies, colour variation, biogeography, Batesian mimicry, citizen science data
Published in DiRROS: 28.03.2023; Views: 523; Downloads: 225
Full text (2,74 MB)
This document has many files! More...

Abstract: Landslide monitoring is a mandatory step in landslide risk assessment. It requires collecting data on landslide conditions (e.g., areal extent, landslide kinematics, surface topography, hydrogeometeorological parameters, and failure surfaces) from different time periods and at different scales, from site-specific to local, regional, and national, to assess landslide activity. In this analysis, we collected information on landslide monitoring techniques from 17 members of the Earth Observation and Geohazards Expert Group (from EuroGeoSurveys) deployed between 2005 and 2021. We examined the types of the 75 recorded landslides, the landslide techniques, spatial resolution, temporal resolution, status of the technique (operational, non-operational), time of using (before the event, during the event, after the event), and the applicability of the technique in early warning systems. The research does not indicate the accuracy of each technique but, rather, the extent to which Geological Surveys conduct landslide monitoring and the predominant techniques used. Among the types of landslides, earth slides predominate and are mostly monitored by geological and engineering geological mapping. The results showed that Geological Surveys mostly utilized more traditional monitoring techniques since they have a broad mandate to collect geological data. In addition, this paper provides new insights into the role of the Geological Surveys on landslide monitoring in Europe and contributes to landslide risk reduction initiatives and commitments (e.g., the Kyoto Landslide Commitment 2020).
Keywords: landslide, monitoring techniques, geological data, Geological Surveys of Europe
Published in DiRROS: 30.01.2023; Views: 550; Downloads: 235
Full text (5,17 MB)

Abstract: Prosthetic devices that replace a lost limb have become increasingly performant in recent years. Recent advances in both software and hardware allow for the decoding of electroencephalogram (EEG) signals to improve the control of active prostheses with brain-computer interfaces (BCI). Most BCI research is focused on the upper body. Although BCI research for the lower extremities has increased in recent years, there are still gaps in our knowledge of the neural patterns associated with lower limb movement. Therefore, the main objective of this study is to show the feasibility of decoding lower limb movements from EEG data recordings. The second aim is to investigate whether well-known neuroplastic adaptations in individuals with an amputation have an influence on decoding performance. To address this, we collected data from multiple individuals with lower limb amputation and a matched able-bodied control group. Using these data, we trained and evaluated common BCI methods that have already been proven effective for upper limb BCI. With an average test decoding accuracy of 84% for both groups, our results show that it is possible to discriminate different lower extremity movements using EEG data with good accuracy. There are no significant differences (p = 0.99) in the decoding performance of these movements between healthy subjects and subjects with lower extremity amputation. These results show the feasibility of using BCI for lower limb prosthesis control and indicate that decoding performance is not influenced by neuroplasticity-induced differences between the two groups.
Keywords: neuroprosthetics, brain-computer interface, machine learning, electroencephalography, data-driven learning, lower limb amputation
Published in DiRROS: 21.07.2022; Views: 567; Downloads: 396
Full text (858,15 KB)
This document has many files! More...

Abstract: Background. Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods. We analysed 2015-2020 MASK-air® European data. We compared days under no medication, monotherapy, and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms (“VAS Global Symptoms”) and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within one year. Results. We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy, and 38,315 (17.3%) under co-medication. The median “VAS Global Symptoms” was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p<0.001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H1-antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. Conclusions. AR medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR), and that co-medication use is driven by symptom severity.
Keywords: asthma -- drug therapy, rhinitis -- drug therapy, allergic rhinitis -- drug therapy, visual analogue scale, histamine antagonists, antihistamines, behavioural patterns, medication patterns, real-world data
Published in DiRROS: 14.03.2022; Views: 659; Downloads: 239
Link to file

Abstract: Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Keywords: non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Europe, Central Europe, Eastern Europe
Published in DiRROS: 15.12.2021; Views: 841; Downloads: 437
Link to file